PDF herunterladen
Am J Perinatol 2014; 31(08): 711-716
DOI: 10.1055/s-0033-1358770
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Evaluating the Side Effects of Treatment for Preterm Labor in a Center that Uses “High-Dose” Magnesium Sulfate

Matthew S. Wilson
1   Department of Obstetrics and Gynecology, Granger Medical Clinic, West Jordan, Utah
,
Melissa Ingersoll
2   Phoenix Perinatal Associates, Phoenix, Arizona
,
Erin Meschter
3   Department of Obstetrics and Gynecology, Good Samaritan Medical Center, Phoenix, Arizona
,
Ana V. Bodea-Braescu
2   Phoenix Perinatal Associates, Phoenix, Arizona
,
Rodney K. Edwards
4   Department of Obstetrics and Gynecology, University of Alabama Birmingham School of Medicine, Birmingham, Alabama
› Institutsangaben
Weitere Informationen

Publikationsverlauf

23. Mai 2013

16. September 2013

Publikationsdatum:
11. Dezember 2013 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Objective To evaluate the tolerability and safety of intravenous magnesium sulfate use for tocolysis in a center that uses a “high-dose” regimen.

Study Design We conducted a retrospective cohort study of patients treated with magnesium sulfate for preterm labor from December 2006 to June 2010. Data were abstracted from review of individual patient electronic medical records.

Results The cohort consisted of 456 women. Of these, 417 (91.4%) experienced side effects. Severe side effects (pulmonary edema, respiratory arrest, intensive care unit transfer, cardiac arrest, or death) occurred in 24 (5.3%) cases, all but one due to pulmonary edema. No cases of respiratory arrest, cardiac arrest, or death occurred. Those with severe side effects were less likely to have a singleton and more likely to have a higher order multifetal gestation (p < 0.001), received more magnesium, and more often were given multiple concurrent tocolytics (p = 0.04).

Conclusion “High-dose” magnesium tocolysis results in side effects for 9 of every 10 patients treated, and severe side effects occur in 1 of every 20 patients. When used for tocolysis, magnesium should be used as a single agent, for less than 48 hours, and with great caution in multifetal gestations.

Keyword

High-dose magnesium side effects

Note

This study was presented as a poster at the 60th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists, San Diego, California, on May 6, 2012.


 

  • References

  • 1 MacDorman MF, Munson ML, Kirmeyer S. Fetal and perinatal mortality, United States, 2004. Natl Vital Stat Rep 2007; 56 (3) 1-19
    PubMedGoogle Scholar
  • 2 Callaghan WM, MacDorman MF, Rasmussen SA, Qin C, Lackritz EM. The contribution of preterm birth to infant mortality rates in the United States. Pediatrics 2006; 118 (4) 1566-1573
    CrossrefPubMedGoogle Scholar
  • 3 Hamilton BE, Martin JA, Ventura SJ. Births: preliminary data for 2011. Natl Vital Stat Rep 2012; 61: 1-20
    PubMedGoogle Scholar
  • 4 Muglia LJ, Katz M. The enigma of spontaneous preterm birth. N Engl J Med 2010; 362 (6) 529-535
    Google Scholar
  • 5 Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Gilstrap LC, Wenstrom KD. Williams Obstetrics. 22nd ed. New York, NY: McGraw-Hill Medical Publishing; 2005: 855-880
    Google Scholar
  • 6 Berkman ND, Thorp Jr JM, Lohr KN , et al. Tocolytic treatment for the management of preterm labor: a review of the evidence. Am J Obstet Gynecol 2003; 188 (6) 1648-1659
    CrossrefPubMedGoogle Scholar
  • 7 Ramsey PS, Rouse DJ. Magnesium sulfate as a tocolytic agent. Semin Perinatol 2001; 25 (4) 236-247
    CrossrefPubMedGoogle Scholar
  • 8 Elliott JP, Lewis DF, Morrison JC, Garite TJ. In defense of magnesium sulfate. Obstet Gynecol 2009; 113 (6) 1341-1348
    CrossrefPubMedGoogle Scholar
  • 9 Haas DM, Imperiale TF, Kirkpatrick PR, Klein RW, Zollinger TW, Golichowski AM. Tocolytic therapy: a meta-analysis and decision analysis. Obstet Gynecol 2009; 113 (3) 585-594
    CrossrefPubMedGoogle Scholar
  • 10 Cotton DB, Strassner HT, Hill LM, Schifrin BS, Paul RH. Comparison of magnesium sulfate, terbutaline and a placebo for inhibition of preterm labor. A randomized study. J Reprod Med 1984; 29 (2) 92-97
    PubMedGoogle Scholar
  • 11 Cox SM, Sherman ML, Leveno KJ. Randomized investigation of magnesium sulfate for prevention of preterm birth. Am J Obstet Gynecol 1990; 163 (3) 767-772
    CrossrefPubMedGoogle Scholar
  • 12 Beall MH, Edgar BW, Paul RH, Smith-Wallace T. A comparison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm labor. Am J Obstet Gynecol 1985; 153 (8) 854-859
    CrossrefPubMedGoogle Scholar
  • 13 Hollander DI, Nagey DA, Pupkin MJ. Magnesium sulfate and ritodrine hydrochloride: a randomized comparison. Am J Obstet Gynecol 1987; 156 (3) 631-637
    CrossrefPubMedGoogle Scholar
  • 14 Miller Jr JM, Keane MW, Horger III EO. A comparison of magnesium sulfate and terbutaline for the arrest of premature labor. A preliminary report. J Reprod Med 1982; 27 (6) 348-351
    PubMedGoogle Scholar
  • 15 Wilkins IA, Lynch L, Mehalek KE, Berkowitz GS, Berkowitz RL. Efficacy and side effects of magnesium sulfate and ritodrine as tocolytic agents. Am J Obstet Gynecol 1988; 159 (3) 685-689
    CrossrefPubMedGoogle Scholar
  • 16 Glock JL, Morales WJ. Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: a randomized study. Am J Obstet Gynecol 1993; 169 (4) 960-964
    CrossrefPubMedGoogle Scholar
  • 17 Larmon JE, Ross BS, May WL, Dickerson GA, Fischer RG, Morrison JC. Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. Am J Obstet Gynecol 1999; 181 (6) 1432-1437
    CrossrefPubMedGoogle Scholar
  • 18 Lyell DJ, Pullen K, Campbell L , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor: a randomized controlled trial. Obstet Gynecol 2007; 110 (1) 61-67
    CrossrefPubMedGoogle Scholar
  • 19 El-Sayed YY, Riley ET, Holbrook Jr RH, Cohen SE, Chitkara U, Druzin ML. Randomized comparison of intravenous nitroglycerin and magnesium sulfate for treatment of preterm labor. Obstet Gynecol 1999; 93 (1) 79-83
    CrossrefPubMedGoogle Scholar
  • 20 McWhorter J, Carlan SJ, OLeary TD, Richichi K, OBrien WF. Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. [published erratum appears in Obstet Gynecol 2004;104:200] Obstet Gynecol 2004; 103 (5, Pt 1) 923-930
    CrossrefPubMedGoogle Scholar
  • 21 Morales WJ, Madhav H. Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. Am J Obstet Gynecol 1993; 169 (1) 97-102
    CrossrefPubMedGoogle Scholar
  • 22 Elliott JP. Magnesium sulfate as a tocolytic agent. Am J Obstet Gynecol 1983; 147 (3) 277-284
    PubMedGoogle Scholar
  • 23 Hueston WJ. Preterm contractions in community settings: II. Predicting preterm birth in women with preterm contractions. Obstet Gynecol 1998; 92 (1) 43-46
    CrossrefPubMedGoogle Scholar
  • 24 Macones GA, Segel SY, Stamilio DM, Morgan MA. Prediction of delivery among women with early preterm labor by means of clinical characteristics alone. Am J Obstet Gynecol 1999; 181 (6) 1414-1418
    CrossrefPubMedGoogle Scholar
  • 25 Peaceman AM, Andrews WW, Thorp JM , et al. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. Am J Obstet Gynecol 1997; 177 (1) 13-18
    CrossrefPubMedGoogle Scholar
  • 26 Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006; 3 (3) CD004454
    PubMedGoogle Scholar
  • 27 Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 2002; 51 (RR-11) 1-22
    PubMedGoogle Scholar
  • 28 Rouse DJ, Hirtz DG, Thom E , et al; Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008; 359 (9) 895-905
    CrossrefPubMedGoogle Scholar
  • 29 Food and Drug Administration. FDA Recommends Against Prolonged Use of Magnesium Sulfate to Stop Pre-Term Labor due to Bone Changes in Exposed Babies. FDA Drug Safety Communication. Silver Spring (MD): FDA; 2013. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM353335.pdf
    PubMedGoogle Scholar
  • 30 Magnesium sulfate use in obstetrics. Committee Opinion No. 573. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013; 122: 727-728
    CrossrefPubMedGoogle Scholar